OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mesa on the Future of JAK Inhibitor Therapy in Myelofibrosis

May 4th 2022

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

Dr. Monk on the Growing Role of Checkpoint Inhibitors in Cervical Cancer

May 4th 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the growing role of checkpoint inhibitors in cervical cancer.

Dr. Mesa on Determinants of Disparities in Cancer Care

May 3rd 2022

Ruben A. Mesa, MD, discusses various determinants of disparities in cancer care.

Dr. Deol on CAR T-Cell Therapy in Earlier Lines of Therapy in Cancer Care

May 3rd 2022

Abhinav Deol, MD, discusses shifting CAR T-cell therapy to earlier lines of therapy in cancer care.

Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL

May 3rd 2022

Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Verstovsek on Addressing Anemia in Patients with Myelofibrosis

May 3rd 2022

Srdan Verstovsek, MD, PhD, discusses addressing anemia in patients with myelofibrosis.

Dr. Grivas on the TROPHY U-01 Trial in Urothelial Cancer

May 2nd 2022

Petros Grivas, MD, PhD, discusses the phase 2 TROPHY U-01 trial in metastatic urothelial cancer.

Dr. Iacovelli on Key Takeaways from the ARIES Trial in Urothelial Cancer

May 2nd 2022

Roberto Iacovelli, MD, PhD, discusses the key takeaways of the phase 2 ARIES trial in urothelial cancer.

Dr. Munver on the Approval of Mitomycin Gel in Urothelial Cancer

April 29th 2022

Ravi Munver, MD, discusses the approval of mitomycin gel in urothelial cancer.

Dr. Olawaiye on How to Address Disparities in Cancer Care

April 29th 2022

Alexander B. Olawaiye, MD, discusses how to address disparities in cancer care.

Dr. Weinberg on Treating Patients with NTRK Fusions in NSCLC

April 29th 2022

Frank Weinberg, MD, PhD, discusses the treatment options in non–small cell lung cancer harboring NTRK fusions.

Dr. Maron on Sequencing Considerations in the Frontline Treatment of GI Cancers

April 28th 2022

Steven Maron, MD, MSc, discusses sequencing considerations in the frontline treatment of gastrointestinal cancers.

Dr. Khan on Racial Disparities with Patient Surgical Outcomes in GI Tract Cancer

April 28th 2022

Sajid A Khan MD, FACS, FSSO, discusses racial disparities with patient surgical outcomes in gastrointestinal tract cancer.

Dr. Edington on the Utilization of TVEC Therapy in Melanoma

April 28th 2022

Howard D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.

Dr. Taylor on Findings from a Genomic Analysis on BTK Inhibitors in CLL

April 27th 2022

Justin W. Taylor, MD, discusses findings from a genomic analysis on BTK inhibitors in chronic lymphocytic leukemia.

Dr. Lee on the Importance of Sequencing in Precision Medicine

April 27th 2022

Kelvin P. Lee, MD, discusses the importance of sequencing in precision medicine.

Dr. Kirkwood on the Use of Ipilimumab/Nivolumab in Melanoma With Brain Metastases

April 26th 2022

John M. Kirkwood, MD, discusses the utilization of ipilimumab and nivolumab in patients with melanoma with brain metastases.

Dr. Armstrong on Updated Results of the ARCHES Trial in mHSPC

April 26th 2022

Andrew J. Armstrong, MD, MSc, discusses updated results from the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

Dr. Huang on Research in ALK+ NSCLC

April 26th 2022

Chao H. Huang, MD, FACP, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer.

Dr. Kalinsky on Strategies to Prevent Recurrence in Early Breast Cancer

April 26th 2022

Kevin Kalinsky, MD, MS, discusses the potential benefits of chemotherapy in preventing disease recurrence in premenopausal patients with breast cancer.